FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149086938> ?p ?o ?g. }

• W2149086938 abstract "Tanzania abandoned sulfadoxine-pyrimethamine (SP) as the first-line treatment for uncomplicated malaria in 2006 due to high levels Plasmodium falciparum resistance. However, SP is still being used for intermittent preventive treatment during pregnancy (IPTp-SP). This study aimed to assess the pattern of P. falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations and associated haplotypes in areas with different malaria transmission intensities in mainland Tanzania, 6 years after withdrawal of SP as a first-line treatment regimen for uncomplicated malaria. A total of 264 samples were collected during cross-sectional surveys in three districts of Muheza, Muleba and Nachingwea in Tanga, Kagera and Lindi regions, respectively. Parasite genomic DNA was extracted from P. falciparum positive samples. The Pfdhfr, Pfdhps single nucleotide polymorphisms (SNPs) were amplified using nested polymerase chain reaction and detected by sequence specific oligonucleotide probe-enzyme linked immunosorbent assay (SSOP-ELISA). The prevalence of the mutant Pfdhfr-Pfdhps haplotypes was heterogenous and transmission dependent. The triple Pfdhfr mutant haplotypes (CIRNI) were predominant in all sites with significantly higher frequencies at Muheza (93.3 %) compared to Muleba (75.0 %) and Nachingwea districts (70.6 %), (p < 0.001). Overall, the prevalence of the wild-type Pfdhps (SAKAA) haplotype was lowest at Muheza (1.3 %), (p = 0.002). Double Pfdhps haplotype SGEAA was significantly high at Muheza (27.2 %) and Muleba (20.8 %) while none (0 %) was detected at Nachingwea (p < 0.001). The prevalence of triple Pfdhps SGEGA haplotype was significantly higher at Muheza compared to Muleba and Nachingwea (p < 0.001). In contrast, Nachingwea and Muleba had significantly higher prevalence of another triple Pfdhps AGEAA haplotype (χ2 = 39.9, p < 0.001). Conversely, Pfdhfr-Pfdhps as quintuple and sextuple haplotypes were predominant including the emergence of a septuple mutant haplotype CIRNI-AGEGA (n = 11) observed at Muheza and Muleba. These results ascertain the high prevalence and saturation of Pfdhfr and Pfdhps haplotypes conferring SP resistance in areas with changing malaria epidemiology; and this could undermine the use of IPTp-SP in improving pregnancy outcomes. In these settings where high level SP resistance is documented, additional control efforts are needed and evaluation of an alternative drug for IPTp is an urgent priority." @default.
• W2149086938 created "2016-06-24" @default.
• W2149086938 creator A5006998049 @default.
• W2149086938 creator A5007020563 @default.
• W2149086938 creator A5009095999 @default.
• W2149086938 creator A5010671425 @default.
• W2149086938 creator A5017672768 @default.
• W2149086938 creator A5056509819 @default.
• W2149086938 creator A5082286959 @default.
• W2149086938 date "2015-11-05" @default.
• W2149086938 modified "2023-10-15" @default.
• W2149086938 title "High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania" @default.
• W2149086938 cites W1541226626 @default.
• W2149086938 cites W1817283835 @default.
• W2149086938 cites W1995029436 @default.
• W2149086938 cites W1996551849 @default.
• W2149086938 cites W2013305623 @default.
• W2149086938 cites W2019358007 @default.
• W2149086938 cites W2021007121 @default.
• W2149086938 cites W2026745106 @default.
• W2149086938 cites W2048102298 @default.
• W2149086938 cites W2056979654 @default.
• W2149086938 cites W2070239562 @default.
• W2149086938 cites W2073059379 @default.
• W2149086938 cites W2076212031 @default.
• W2149086938 cites W2079127050 @default.
• W2149086938 cites W2080452727 @default.
• W2149086938 cites W2087956351 @default.
• W2149086938 cites W2099198335 @default.
• W2149086938 cites W2101302800 @default.
• W2149086938 cites W2106552226 @default.
• W2149086938 cites W2116792146 @default.
• W2149086938 cites W2118248316 @default.
• W2149086938 cites W2123470783 @default.
• W2149086938 cites W2123887868 @default.
• W2149086938 cites W2123912194 @default.
• W2149086938 cites W2124270158 @default.
• W2149086938 cites W2124634096 @default.
• W2149086938 cites W2125629663 @default.
• W2149086938 cites W2127733438 @default.
• W2149086938 cites W2131902613 @default.
• W2149086938 cites W2135192999 @default.
• W2149086938 cites W2141917084 @default.
• W2149086938 cites W2142611140 @default.
• W2149086938 cites W2144961504 @default.
• W2149086938 cites W2150128419 @default.
• W2149086938 cites W2151507439 @default.
• W2149086938 cites W2156450423 @default.
• W2149086938 cites W2157068434 @default.
• W2149086938 cites W2158858181 @default.
• W2149086938 cites W2160666828 @default.
• W2149086938 cites W2161070536 @default.
• W2149086938 cites W2164187904 @default.
• W2149086938 cites W2166242323 @default.
• W2149086938 cites W2167296967 @default.
• W2149086938 cites W2170637247 @default.
• W2149086938 cites W2171222174 @default.
• W2149086938 cites W2792449494 @default.
• W2149086938 cites W69390791 @default.
• W2149086938 doi "https://doi.org/10.1186/s12936-015-0977-8" @default.
• W2149086938 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4635599" @default.
• W2149086938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26542942" @default.
• W2149086938 hasPublicationYear "2015" @default.
• W2149086938 type Work @default.
• W2149086938 sameAs 2149086938 @default.
• W2149086938 citedByCount "30" @default.
• W2149086938 countsByYear W21490869382016 @default.
• W2149086938 countsByYear W21490869382017 @default.
• W2149086938 countsByYear W21490869382019 @default.
• W2149086938 countsByYear W21490869382020 @default.
• W2149086938 countsByYear W21490869382021 @default.
• W2149086938 countsByYear W21490869382022 @default.
• W2149086938 countsByYear W21490869382023 @default.
• W2149086938 crossrefType "journal-article" @default.
• W2149086938 hasAuthorship W2149086938A5006998049 @default.
• W2149086938 hasAuthorship W2149086938A5007020563 @default.
• W2149086938 hasAuthorship W2149086938A5009095999 @default.
• W2149086938 hasAuthorship W2149086938A5010671425 @default.
• W2149086938 hasAuthorship W2149086938A5017672768 @default.
• W2149086938 hasAuthorship W2149086938A5056509819 @default.
• W2149086938 hasAuthorship W2149086938A5082286959 @default.
• W2149086938 hasBestOaLocation W21490869381 @default.
• W2149086938 hasConcept C104317684 @default.
• W2149086938 hasConcept C135763542 @default.
• W2149086938 hasConcept C159047783 @default.
• W2149086938 hasConcept C197754878 @default.
• W2149086938 hasConcept C203014093 @default.
• W2149086938 hasConcept C2776120307 @default.
• W2149086938 hasConcept C2777035104 @default.
• W2149086938 hasConcept C2777234095 @default.
• W2149086938 hasConcept C2777616469 @default.
• W2149086938 hasConcept C2778048844 @default.
• W2149086938 hasConcept C2778301690 @default.
• W2149086938 hasConcept C2778371730 @default.
• W2149086938 hasConcept C2780441369 @default.
• W2149086938 hasConcept C54355233 @default.
• W2149086938 hasConcept C86803240 @default.
• W2149086938 hasConceptScore W2149086938C104317684 @default.
• W2149086938 hasConceptScore W2149086938C135763542 @default.
• W2149086938 hasConceptScore W2149086938C159047783 @default.

• next